← All trials
NCT05248893
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2022
- Primary completion
- Jan 29, 2023
- Completion date
- Jan 29, 2023
- First posted
- Feb 21, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 880
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.